Other languages Esperion Therapeutics, Inc.

Equities

ESPR

US29664W1053

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
2.8 ^USD	+13.36%		+29.63%	-6.35%

May. 22	Daiichi Sankyo Europe GmbH and Esperion Therapeutics, Inc. Jointly Announce That European Commission Has Approved the Label Update of Both NILEMDO® (bempedoic acid) and NUSTENDI® (bempedoic acid / ezetimibe fixed-dose combination), as Treatments for Hypercholesterolemia and to Reduce the Risk of Adverse Cardiovascular Events	CI
May. 20	Esperion Therapeutics Says Primary Endpoint Achieved in Hypercholesterolemia Treatment Phase 3 Trial; Shares Rise	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Daiichi Sankyo Europe GmbH and Esperion Therapeutics, Inc. Jointly Announce That European Commission Has Approved the Label Update of Both NILEMDO® (bempedoic acid) and NUSTENDI® (bempedoic acid / ezetimibe fixed-dose combination), as Treatments for Hypercholesterolemia and to Reduce the Risk of Adverse Cardiovascular Events	May. 22
Esperion Therapeutics Says Primary Endpoint Achieved in Hypercholesterolemia Treatment Phase 3 Trial; Shares Rise	May. 20
Investor Sentiment Muted After Rate Cut Optimism, Stifling US Equity Futures Pre-Bell	May. 07
Top Premarket Gainers	May. 07
Esperion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07
Sector Update: Health Care Stocks Steady Premarket Monday	Mar. 25
Top Premarket Gainers	Mar. 25
U.S. FDA Approves Broad New Labels for Esperion?s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use	Mar. 22
Esperion Therapeutics Shares Rise After US FDA Expands Labels for Nexletol, Nexlizet	Mar. 22
Esperion, Daiichi Get EU Committee Recommendation For Nilemdo, Nustendi Label Update	Mar. 22
Daiichi Sankyo Europe GmbH and Esperion Therapeutics, Inc. Announces CHMP Adopts Positive Opinions for the Label Update of Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Fixed Dose Combination	Mar. 22
Esperion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27
Esperion Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27
Wall Street Set to Open Higher Friday Ahead of Consumer Sentiment, Home Sales Data	Jan. 19
US Futures Trend Higher as Investors Await Consumer Sentiment, Home Sales Data	Jan. 19
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Amid Tech Stocks Gains	Jan. 19
Top Premarket Decliners	Jan. 19
Esperion Therapeutics Prices $85.1 Million Share Offering	Jan. 19
Esperion Therapeutics Launches Share Offering	Jan. 18
Top Midday Decliners	Jan. 03

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Esperion Therapeutics, Inc.

Equities

ESPR

US29664W1053

Other languages

Filters